Dacomitinib Anhydrous vs Pembrolizumab

## Dacomitinib Anhydrous vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between **Dacomitinib Anhydrous** and **Pembrolizumab**.

## Mechanism of Action

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

## Pharmacokinetics

**Half-life**: Dacomitinib Anhydrous — N/A; Pembrolizumab — 26 days.

## Chemical Properties

**Type**: Dacomitinib Anhydrous — Small molecule; Pembrolizumab — Antibody.